vs
BridgeBio Pharma, Inc.（BBIO）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
BridgeBio Pharma, Inc.的季度营收约是STURM RUGER & CO INC的1.0倍（$154.2M vs $151.1M），BridgeBio Pharma, Inc.同比增速更快（2521.2% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-56.5M）
本文提供的介绍实际对应 Brent Saunders 的个人履历，而非BridgeBio Pharma, Inc. 的企业信息。Brent Saunders是美国生物制药行业高管与企业家，目前担任博士伦公司董事长兼首席执行官，曾主导参与多起大型医药并购交易，同时涉足特殊目的收购公司领域，在医疗板块拥有丰富行业经验。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
BBIO vs RGR — 直观对比
营收规模更大
BBIO
是对方的1.0倍
$151.1M
营收增速更快
BBIO
高出2517.6%
3.6%
自由现金流更多
RGR
多$68.8M
$-56.5M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $154.2M | $151.1M |
| 净利润 | $-194.6M | — |
| 毛利率 | 94.7% | 17.8% |
| 营业利润率 | -90.5% | 2.3% |
| 净利率 | -126.2% | — |
| 营收同比 | 2521.2% | 3.6% |
| 净利润同比 | 27.2% | — |
| 每股收益（稀释后） | $-1.00 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBIORGR
| Q4 25 | $154.2M | $151.1M | ||
| Q3 25 | $120.7M | $126.8M | ||
| Q2 25 | $110.6M | $132.5M | ||
| Q1 25 | $116.6M | $135.7M | ||
| Q4 24 | — | $145.8M | ||
| Q3 24 | — | $122.3M | ||
| Q2 24 | — | $130.8M | ||
| Q1 24 | $211.1M | $136.8M |
净利润BBIORGR
| Q4 25 | $-194.6M | — | ||
| Q3 25 | $-184.9M | $1.6M | ||
| Q2 25 | $-183.8M | $-17.2M | ||
| Q1 25 | $-169.6M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | $-36.2M | $7.1M |
毛利率BBIORGR
| Q4 25 | 94.7% | 17.8% | ||
| Q3 25 | 94.6% | 15.1% | ||
| Q2 25 | 96.7% | 3.9% | ||
| Q1 25 | 97.7% | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | 99.7% | 21.5% |
营业利润率BBIORGR
| Q4 25 | -90.5% | 2.3% | ||
| Q3 25 | -120.3% | -2.7% | ||
| Q2 25 | -121.4% | -15.6% | ||
| Q1 25 | -89.5% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | 0.2% | 5.5% |
净利率BBIORGR
| Q4 25 | -126.2% | — | ||
| Q3 25 | -153.2% | 1.2% | ||
| Q2 25 | -166.2% | -13.0% | ||
| Q1 25 | -145.4% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | -17.1% | 5.2% |
每股收益（稀释后）BBIORGR
| Q4 25 | $-1.00 | $0.22 | ||
| Q3 25 | $-0.95 | $0.10 | ||
| Q2 25 | $-0.95 | $-1.05 | ||
| Q1 25 | $-0.88 | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | $-0.20 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $570.1M | $92.5M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $-2.1B | $283.8M |
| 总资产 | $936.0M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BBIORGR
| Q4 25 | $570.1M | $92.5M | ||
| Q3 25 | $643.0M | $80.8M | ||
| Q2 25 | $756.9M | $101.4M | ||
| Q1 25 | $540.6M | $108.3M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $96.0M | ||
| Q2 24 | — | $105.6M | ||
| Q1 24 | $519.7M | $115.3M |
总债务BBIORGR
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BBIORGR
| Q4 25 | $-2.1B | $283.8M | ||
| Q3 25 | $-1.9B | $279.6M | ||
| Q2 25 | $-1.8B | $289.3M | ||
| Q1 25 | $-1.6B | $321.5M | ||
| Q4 24 | — | $319.6M | ||
| Q3 24 | — | $314.9M | ||
| Q2 24 | — | $321.5M | ||
| Q1 24 | $-1.0B | $332.0M |
总资产BBIORGR
| Q4 25 | $936.0M | $342.0M | ||
| Q3 25 | $998.3M | $342.3M | ||
| Q2 25 | $1.1B | $349.5M | ||
| Q1 25 | $881.6M | $379.0M | ||
| Q4 24 | — | $384.0M | ||
| Q3 24 | — | $373.5M | ||
| Q2 24 | — | $376.7M | ||
| Q1 24 | $849.3M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-56.4M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-56.5M | $12.3M |
| 自由现金流率自由现金流/营收 | -36.6% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流BBIORGR
| Q4 25 | $-56.4M | $15.5M | ||
| Q3 25 | $-109.6M | $12.9M | ||
| Q2 25 | $-80.7M | $14.7M | ||
| Q1 25 | $-199.2M | $11.1M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | $-219.5M | $7.3M |
自由现金流BBIORGR
| Q4 25 | $-56.5M | $12.3M | ||
| Q3 25 | $-110.0M | $7.0M | ||
| Q2 25 | $-81.3M | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | $-220.2M | $5.6M |
自由现金流率BBIORGR
| Q4 25 | -36.6% | 8.2% | ||
| Q3 25 | -91.2% | 5.5% | ||
| Q2 25 | -73.5% | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | -104.3% | 4.1% |
资本支出强度BBIORGR
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.4% | 4.6% | ||
| Q2 25 | 0.5% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | 0.3% | 1.3% |
现金转化率BBIORGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BBIO
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
